Literature DB >> 29661335

Head and Neck Cancer in the Elderly: Frailty, Shared Decisions, and Avoidance of Low Value Care.

Leila J Mady1, Marci L Nilsen2, Jonas T Johnson3.   

Abstract

Head and neck cancer (HNC) is a disease of older adults. Recurrent and metastatic head and neck squamous cell carcinoma portends a poor prognosis, with median overall survival of less than 12 months. Within this vulnerable population, significant treatment-related toxicities and physical and psychosocial sequelae can be devastating to quality of life at the end of life. Shared decision making and early comprehensive palliative and support services are at the crux of the approach to older adults with HNC. In doing so, low-value care that fails to meet the goals of patients and their caregivers at the end-of-life may be avoided.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Frailty; Head and neck cancer; Older adult oncology; Patient-centered care; Shared decision making; Supportive and palliative care

Mesh:

Year:  2018        PMID: 29661335     DOI: 10.1016/j.cger.2018.01.003

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN: 0749-0690            Impact factor:   3.076


  3 in total

Review 1.  Special considerations for elderly patients with head and neck cancer during the COVID-19 pandemic.

Authors:  Arun Sharma; Dana L Crosby
Journal:  Head Neck       Date:  2020-04-28       Impact factor: 3.147

2.  Cytoplasmic eIF6 promotes OSCC malignant behavior through AKT pathway.

Authors:  Zechen Zhao; Weiming Chu; Yang Zheng; Chao Wang; Yuemei Yang; Teng Xu; Xueming Yang; Wei Zhang; Xu Ding; Gang Li; Hongchuang Zhang; Junbo Zhou; Jinhai Ye; Heming Wu; Xiaomeng Song; Yunong Wu
Journal:  Cell Commun Signal       Date:  2021-12-18       Impact factor: 5.712

3.  Impact of adjuvant radiation therapy after definitive surgery in senior adults >80 years old with advanced head and neck squamous cell carcinoma on overall survival.

Authors:  Joann M Butkus; Meghan Crippen; Voichita Bar-Ad; Adam Luginbuhl
Journal:  Front Oncol       Date:  2022-09-30       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.